Clinical treatment of newly diagnosed multiple myeloma.
The introduction of the novel agents, thalidomide, bortezomib and lenalidomide as part of the frontline induction both in transplant and non-transplant candidates have markedly improved the anti-myeloma efficacy of the different therapeutic regimens and improved patients' prognosis. Current treatment goals are aimed to further improve the rate of complete remission, time to progression, progression-free survival and overall survival without increasing toxicity. Besides, different strategies are being developed in the elderly population as this group of patients requires a closer monitoring with individualized, dose-modified regimens to improve tolerability while maintaining their quality of life. This article reviews the current landscape of frontline treatment both in transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma.
a 1 Hematology Service, University Hospital Doctor Peset, Valencia, Spain.
María J
MJ
Cejalvo
Javier
J
de la Rubia
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060830:Consolidation Chemotherapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
frontline therapy; multiple myeloma; newly diagnosed